Below you can find more information about our recent Press Releases and Publications
March, 2020: PepVax is developing an immunotherapy, to both help patients suffering from the illness and protect healthy people from contracting it...Read more
September, 2019: PepVax has developed SMARTmid, a “Trojan Horse” drug delivery platform for DNA and RNA based treatments...Read more
August, 2018: PepVax has developed SMARTmid, a “Trojan Horse” drug delivery platform for DNA and RNA based treatments...Read more
August, 2018: Five years after opening a $50,000 crowdfunding campaign for his biotech, Mahesh Narayanan has launched the drug delivery platform it was intended to fund...Read more
January, 2018: PepVax, Inc., an early-stage biotechnology company, announced today that it has successfully completed the efficacy study for its lead candidate, PVX-009....Read more
October, 2017: Mid-Atlantic Bio Angels (MABA) announces today that PepVax, Inc. (http://www.pepvax.co), which is developing a therapeutic treatment against triple negative breast cancer (TNBC), was named “Best in Show”...Read more
August, 2017: PepVax, Inc., an early-stage biotechnology company, announced today that it has initiated its in vivo efficacy study for lead candidate, PVX-009...Read more
July, 2017: PepVax, Inc., an early stage biotechnology company developing an immunotherapy treatment for triple-negative breast cancer (TNBC), today announced several new milestones and upcoming events that demonstrate the company's continued growth...Read more
The Maryland Entrepreneurs Resource List (MERL) started in 2012 and has had some recent success in providing leadership to early stage companies. One example is Ocular Proteomics, LLC, OPL. Joshua Hines, business director for OPL, has contacted several MERL...Read more
Biotech and crowdfunding don't sound particularly compatible. The staggering research, clinical and regulatory costs associated with putting "pill number one" on the market seems like it would prevent a Kickstarter or Indiegogo campaign, especially since trading equity for funding isn't legal yet... Read more
Achinko DA, Narayanan M, Norman EF, Anton Dormer (2020) Genetic Association between HERV-H LTR Associating 2 (HHLA2) Protein and MAGE-B5 Variant in Viral Related Diseases. J Hum Genet Genomic Med 1: 105...Read more
June, 2015: Paper published by PepVax describing the Epitope specificity and protein signaling interactions driving epidemic occurrences of Ebola disease. Ebolavirus has as main hosts, humans and nonhuman primates where its pathogenic effects result to serious hemorrhagic fever with lethal...Read more
August, 2014: Paper published by PepVax describing a novel strategy of In silico peptide vaccine design for Streptococcus mutans. Several attempts have been made towards the development of a viable vaccine for Streptococcus mutans (S. Mutans). This Gram positive bacterium is...Read more